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As practitioners and policy makers struggle to manage the risks and harms of overdiagnosis, 
Chris Degeling and colleagues contend that Citizens/Community Juries offer a way forward  
 
Unnecessary and harmful interventions from overdiagnosis challenge the social and ethical 
contract that underpins healthcare.1 2 Strategies to address overdiagnosis from population 
screening should engage with and consider public values and concerns.3 Most high-income 
countries develop evidence-based policies to guide population screening using stringent 
criteria that are applied by expert panels to review the available technical evidence. Similarly, 
if perhaps not so systematically, expert panels collect and analyse pathophysiological and 
clinical evidence to determine disease thresholds and definitions.4 But in both cases the final 
judgement as to the acceptability and legitimacy of different screening policies and disease 
definitions are informed by the values of the decision-makers, because the relative balance of 
harms and benefits of making changes are also subjectively weighed and valued.5-7 Putting 
matters to the public promotes greater social and political engagement, public accountability 
and confidence in the decision ultimately made. 
Public engagement occurs on a spectrum of participation in events that aim to consult the 
public (consumer forums/patient groups) to more formal deliberative methods such as 
citizens/community juries (CJs) that seek to bring lay-people into structured deliberation to 
address key complex problems (Textbox 1).8 In this paper, we explore some of the advantages 
and limitations of using CJs to inform policy making in the complex policy areas of 
overdiagnosis.   
The value-add of convening CJs to consider screening and overdiagnosis  
In relation to overdiagnosis CJs have been primarily convened by health researchers, and as 
such should be viewed as providing research evidence for policy making that articulates values 
and explains the reasoning and preferences of an informed public. CJs are appropriate when 
the evidence is uncertain and there is disagreement as to its implications among experts, 
stakeholder groups, or both.  For those charged with screening guideline development, CJs can 
help them understand why patients go against expert advice, and inform them of the factors 
that need to be explained and explicitly considered to retain public trust. CJs are designed to 
allow participants to first be informed, and then to discuss, reflect and clarify their own views 
about the issue at hand rather than recording people’s top-of-mind or intuitive reactions to 
contentious problems (like focus groups or mass surveys) 
In response to the question: “Should the government offer free mammography screening to all 
women aged 40-49?” surveys would likely capture the prevailing public mood as to the 
importance of helping women access preventive health services rather than a nuanced view 
on the implications of lowering the age-related entry point for the national mammography 
screening program. In a CJ convened in Otago New Zealand to answer this question, which was 
comprised of women who had never participated in screening, almost all of the women had 
been in favour of mammography screening for women aged 40-49 at the start of the jury. 
However, by the end of their deliberations the CJ voted 10 to 1 against the proposal to lower 
the entry age because of the potential for harms and the lack of evidence of lives saved in that 
age group.10 (Table Example #1)  
CJs also highlight public values and social concerns that are not part of the evidence-base, but 
nevertheless could be of great importance to policy implementation. For example, two CJs 
comprised of Australian women aged 70-74 (Table Example #3) voted to retain invitations to 
participate in mammography screening services for their age-group, explicitly placing a low 
priority on the potential for overdiagnosis in their decision-making.11 The reasons the jurors 
provided show how organised preventive health services have great symbolic value once 
established, and epidemiological evidence of an unfavourable balance of benefit to harm may 
not be enough to convince people of the need for discontinuation.  
 
Although independent evidence-based expert advice on population screening is essential, 
good policy also relies on public trust. Through their exposure to evidence and expert opinion, 
the participants in these CJs about mammography understood that for population screening 
services to be effective there needs to be tolerance for some level of overdiagnosis. The 
women’s tolerance level however appeared to be higher than that of the clinical research 
experts who were advising against screening. The benefits of screening, as well as the harms 
of screening-related overdiagnosis are experienced by otherwise healthy people. For reasons 
of transparency and accountability the values and priorities of potential service users should 
be considered and addressed in guideline development and program implementation.   
Choosing jurors, types of evidence, and framing jury questions  
The policy relevance of a CJ convened to address an important issue such as overdiagnosis will 
depend on three important factors: how the topic or question is posed; who sits on the jury 
and how they are recruited; and the engagement of policy decision makers.  
Framing a question for the jurors to address  
In the CJs we have conducted on screening and overdiagnosis the question, expert witnesses, 
and the evidence presented to jurors were determined by a steering committee comprised of 
neutral experts, and representatives of stakeholders from each side of the existing debates. 
The committee, organisers and expert witnesses worked together to ensure that the question 
put to jury was framed as ‘neutrally’ as possible so that the verdict was less likely to be 
subsequently dismissed. The quality and reputation of the experts who provided the 
testimony, and the structured process through which they reviewed and moderated one 
another’s presentations helped to ensure that all views presented to jurors were relevant, and 
could be argued from the evidence.   
Not every issue is suitable for deliberation by a CJ. Broadly speaking CJs on screening and 
overdiagnosis have addressed two somewhat different but overlapping policy questions: those 
that explicitly focus on resource allocation (Example #1), and, those about which policy options 
are most justifiable and perceived to be legitimate (Examples #2-5).12 CJs are most useful for 
public engagement when the policy options require a deep consideration of both values and 
evidence.13 
Juror characteristics and the type of evidence produced 
CJs construct a form of mini-public, such that composition of participants will determine what 
kind of claims about ‘representativeness’ can be made about outcome. Three CJs held in 
Sydney Australia on PSA testing and overdiagnosis risks illustrate the difference between CJs 
composed of ‘targeted’ versus ‘general’ publics (Example #4).14  
One of the CJs was comprised of men of screening age (potential PSA test users) and two were 
comprised of participants of mixed genders and ages. All prioritised allocating resources to 
support GPs to adopt an active role in supporting individual men to make decisions about PSA. 
However, in Sydney the two CJs comprising a range of citizens wanted all the information on 
potential harms and benefits of PSA testing to be provided to men before they took the PSA 
test.  Whereas the all-male CJ of potential PSA test users did not want men burdened with 
uncertain and detailed information about risks associated with diagnosis and treatment until 
they had an adverse test result. This example illustrates how a jury comprised of service-users  
can provide a different perspective and insights into a different recommendation to that of a 
jury comprised of members of the public who may not be directly affected by the outcome.  
The findings of juries comprised of service users provide insights into what changes to the 
status quo are likely to be acceptable to those affected. Juries comprising a broader range of 
citizens tend to reveal broader considerations, including the range of issues that may be 
important for weighing the fairness of resource re-allocation against a background of 
competing priorities.8  
Involvement by policy decision makers 
The CJs described in Table 1 were researcher-initiated but all involved clinical and policy 
stakeholders as expert witnesses and/or members of the steering committee. Public 
deliberation aimed at informing policy decisions around overdiagnosis should ideally involve 
the decision makers in the design or implementation, and a subsequent process of ‘translation’ 
or knowledge mobilisation may be required.15 This is not to suggest that decision makers who 
engage with CJs should be bound by the jury verdict, or that CJs cannot be legitimately done 
purely as research. But CJs are more likely to inform policy decisions if those involved recognise 
the value, role and limitations of the jury outcomes in larger political processes.16 Individual 
clinicians and healthcare managers practicing in the field considered by a CJ may also find value 
in such research as a form of synthesis of the diverse values that patients may consider when 
weighing up screening decisions.  
Informing policy aimed at addressing overdiagnosis  
Where expert opinion and public opinion diverge, CJs are valuable for understanding why and 
potentially informing future decisions about public communication and service delivery 
requirements to address patient concerns. The provision of factual information, exposure to 
well-reasoned and sometimes opposing expert opinions, and commitment to working through 
persistent disagreements (rather than dismissing them as deficits in understanding) can help 
to rebalance the information gaps about overdiagnosis and the discrepancy of power between 
experts, decision-makers and the community affected.18 19  
As an authorship team, we have between us conducted more than 15 citizens’ juries, several 
of which have considered overdiagnosis.11 14 20-22  A consistent observation has been that 
members of the public report great surprise at the level of uncertainty embedded in medical 
practice. And particularly how new technologies / medical tests can create more uncertainties, 
rather than resolve concerns. Most people in high income countries like Australia are 
encultured to trust medical tests and trust their doctors.23 They believe that doctors know the 
‘right’ thing to do.24 Trust in their doctors is inevitably the resource that people draw on when 
decisions need to be made in conditions of conflicting or uncertain evidence.  CJs enable them 
to pull back the curtain on medical evidence and thus engage more meaningfully in screening 
policy debates. In our experience, during deliberations people first looked for the embedded 
interests that could drive apparent differences in expert opinion. But ultimately most jurors 
came to both understand and feel sympathy for GPs and other care providers who must 
manage medical uncertainty on a day-to-day basis.  
Conclusions 
If done well CJs are an effective means to conduct research that inform guideline development 
for population screening and disease threshold determination.12 25 Much could be achieved to 
address the social and ethical dimensions of overdiagnosis if those charged with organising and 
regulating these processes made a commitment to formally consider the values and 
preferences of well-informed members of the public and understand the complex trade-offs 
entailed. Procedurally CJ are explicit about the limits of medicine and the pervasiveness of 
medical uncertainty. This fits with the basic tenets of EBM,26 27 and offers an authentic means 
to address the risks and benefits of screening, and issues related to overdiagnosis.28 In addition, 
CJs potentially uncover how health services have other forms of value to the public, which 
need to be explicitly addressed and accounted for in the implementation of policy.29 Bringing 
the public into deliberation about overdiagnosis can broaden and improve the dialogue and 
make the reasons for decisions about resource allocation and potential withdrawal of services 
more clear and transparent, thus promoting public trust and partnerships at a time when trust 
in science and medical expertise appears to be in decline.30-32  
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Key Messages  
 
• Overdiagnosis challenges the social contract that underpins healthcare, and community 
voices are often missing from the relevant policy discussions.  
• Citizens/Community Juries (CJs) elicit the voices, values and preferences of 
informed citizens who are presented with evidence-based expert views, which the jurors 
deliberate among themselves before formulating their opinions and recommendations. 
• CJs are an effective means to study public values that can be used to inform policies and 
practices to manage the risks of overdiagnosis, and to contribute to guideline 
development and proposed changes to disease thresholds. 
• CJ processes align with the basic tenets of EBM, and can broaden and improve the dialogue 
around medical uncertainty, thus promoting public trust and partnerships at a time when 
trust in medicine is declining. 
  
Textbox 1: The characteristics of citizens’ juries (CJs) 
First developed by the Jefferson Centre in 1970s, CJs have been used to address issues such 
as reproductive technology, xenotransplantation, biobanking,8 13 25 and on overdiagnosis.10 
11 14 20  There are a number of different CJ approaches but at a minimum, a group of 12-15 
people are selected to meet over 2-4 days to consider and respond to a specific question. It 
is an issue, rather than an individual, that is “on trial”.33 All CJs have two phases: the first 
focuses on educating participants, the second on deliberation.  During the first phase jurors 
are provided with balanced factual information from expert witnesses (of whom they can 
ask questions and seek clarification), such that a diverse range of potentially conflicting 
perspectives are considered.25 34 Drawing on the evidence presented, during the second 
phase the group work together in facilitated session to produce a verdict or set of 
recommendations.. CJs create the conditions for people to move beyond superficial 
arguments and suspicion of vested interests to understand the complexity of medical 
decision making, and then reflect on their own values and what is important to their 
communities. Consensus is encouraged but not essential; dissenting views and minority 
positions are included in the final report.  
What distinguishes deliberative methods from other forms of public engagement is a 
process of iterative two-way exchange between representatives of the public and the 
deliberation sponsor (researchers, government or other agencies). In theory, the 
deliberative process informs and extends participants’ thinking beyond their own interests 
to consider the collective needs of the community and common or public goods.  Like all 
engagement methods however, CJs have been subjected to critique.35-38 The most common 
concerns are about the representativeness of the selected group and whether a group of 
lay-people can overcome deficits in expertise to make judgements that truly reflect their 
values and informed preferences.  It is important to recognise that CJs of 12-24 people 
cannot possibly represent a statistically characterised sample of ‘the general public’ or the 
prevalence of views. Rather, they offer insights into how and why informed citizens prioritise 
concerns about complex issues like overdiagnosis, and provide explanations for divergence 
in opinions. CJ participants should be recruited to capture diversity of experiences and 
backgrounds in a community, and the deliberation processes organised so as to redress 
power imbalances as much as is feasible.39  When conducted in this way, CJs can reveal and 
capture key community concerns and arguments about current / proposed policy directions 
and enhance accountability in decision-making.   
Table 1: Key issues and questions pertinent to Overdiagnosis that have been addressed by Citizens/Community (CJs) Juries in Australasia 
Key Issue  Sponsors of and reasons 
for the jury or juries    
Question put to the jury or juries / 
Jury characteristics   
Verdict(s)  Novel insights 
Should 
governments 
fund cancer 
screening 
services for 
populations at 
higher risk of 
Overdiagnosis  
  
Example #1 
Convened by health 
researchers in New 
Zealand to explore the use 
of CJs to inform the 
development of 
population screening 
policy.  
 
 
Should the government offer free 
mammography screening to all 
women aged 40-49? 
 
1 jury (n=11); all-female aged 40-49, with no 
previous diagnosis of breast cancer.  
 
[See REF 10 for more details] 
 
The jury voted (10-1) against 
government provision of 
mammography screening to this age 
group  
 
Conducted in 2008, this jury established the 
viability of the CJ method to engage members of 
the public in deliberations about how to manage 
Overdiagnosis. Women who were almost all 
initially in favour of screening for women aged 40-
49 changed their minds because of the potential 
for harms and the lack of evidence of lives saved 
in this age group. The findings revealed how 
women weighed the benefits and harms, and how 
withdrawing an existing service is more 
challenging than not offering it in the first place.  
What are the 
values and 
priorities that 
should guide 
decision making 
around the 
promotion of 
participation in 
screening 
services 
Example #2 
Convened by health 
researchers in Australia 
and funded by the 
National Health & Medical 
Research Council (NHMRC) 
to examine informed 
men’s views about the 
benefits and harms of PSA 
testing. Also established to 
further examine the value 
of CJs for informing 
screening policy.  
Should government campaigns be 
provided (on PSA screening) and if 
so, what information should be 
included in those campaigns?  
 
1 jury (n=11); all male aged 50-70, with no 
previous diagnosis of prostate cancer 
[See REFS 20 & 22 for more details] 
The jury voted unanimously against 
government information campaigns, 
and against an invitation program for 
PSA testing.  
Instead the CJ proposed a campaign 
targeting GPs to assist them to 
provide better quality and more 
consistent information to their 
patients.  
Men’s unanimous agreement on 
information provided by 
Governments and GPs contrasted 
with the diversity in men’s individual 
preferences on whether or not they 
get screened themselves. 
Men prefer to get information about PSA 
screening directly from their GPs. There was 
significant concern about the discrepancy and 
variability in quality of the information available 
to men, and that some GPs were currently not 
following evidence-based guidelines.  
The study illustrated that informed publics are 
clearly able to distinguish between personal 
preferences, and deliberating to formulate 
recommendations regarding a public good.  
A quantitative analysis of the same study 
demonstrates that expert provision of 
information altered CJ participant’s intentions to 
screen compared with written information from 
Cancer Council Australia and Andrology Australia. 
Example #3 
Convened by health 
researchers in Australia 
and funded by the NHMRC 
Should the organized breast cancer 
screening program continue to 
invite and promote screening to 
Both community juries of women 
aged 70-74 found by a majority 
verdict (16-to-2 and 10-to-6) that 
invitations to participate in screening 
These women valued being invited to screen: 
invitations were thought to provide an 
opportunity to access information to enable 
choice, and to demonstrate that society 
to elicit the informed views 
of older women on the 
acceptability of ceasing to 
invite them to use breast 
cancer screening services 
 
Contributions from the Cancer 
Council of Australia.     
women 70-74 without cost to 
participating women 
 
2 juries (n=34); both all-female aged 70-74, 
with no previous diagnosis of breast cancer  
[See REF 11 for more details] 
should continue to be sent to 
women in their age group.  
 
recognised and supported older citizens. 
Evidence that an intervention potentially does 
more harm than good may not be enough to 
convince people to give it up: the study revealed 
other values people may consider important, 
such as older women being valued and 
continuing to be offered the same options and 
choices as younger women.  
How should 
care-providers 
and 
asymptomatic 
patients manage 
the risks of 
Overdiagnosis at 
the point care 
Example #4 
Convened by health 
researchers in Australia 
and funded by the NHMRC 
to elicit the informed 
preferences of citizens and 
potential service users as 
to how PSA testing of 
asymptomatic men should 
be managed in general 
practice 
 
Contributions from the Prostate 
Cancer Foundation of Australia.  
Should GPs introduce the topic of 
PSA testing during appointments 
with male patients who have no 
symptoms? Or should they wait 
until men ask about it? 14 
 
3 juries (n=40) - 2 of mixed genders and ages 
and 1 all male jury aged 37-74 with no 
participants with an experience of a prostate 
cancer diagnosis 
 
[See REFS 14 for more details] 
In contrast with the Royal Australian 
College of General Practitioner 
guidelines, all juries concluded (by 
majority vote) that GPs in Australia 
should initiate discussions about PSA 
testing with asymptomatic men over 
50.  
While GPs might resist raising questions about 
PSA testing, an informed public prefers them to 
take on this responsibility because in Australia 
there is already so much divergent advice in the 
public sphere – and doctors are perceived as the 
best placed inform and explain the risks and 
benefits. Juries consistently agreed that 
discussions with their GP was better than men 
relying on finding out (or not) about the PSA and 
the risks of Overdiagnosis from other sources. 
Example #5 
Convened by health 
researchers in Australia 
and funded by Bond 
University to explore 
informed community 
perspectives around 
current Australian GP 
practices of case-finding 
for dementia 
Should the health system encourage 
General Practitioners to practice 
“case-finding” of dementia in people 
older than 50? 
 
1 jury (n=10); mixed genders aged 50 to 70; 
with no participants (or their immediate 
family) with an experience of Alzheimer’s, 
Mild Cognitive Impairment diagnoses or 
caring for an individual with these diagnoses. 
 
[See REFS 22 for more details] 
In contrast with the Royal Australian 
College of General Practitioner 
guidelines, the jury voted 
unanimously against “case-finding” 
for dementia by GPs. Participants 
cited lack of effective treatments, 
potential to negatively impact mental 
health. Although they disagree with 
“case-finding” as it was currently 
practiced, CJ participants drafted a 
set of recommendations to improve 
future guidelines.  
CJ participants decided to go beyond the CJ 
question and suggested alterations to the RACGP 
guidelines in an attempt to reduce potential 
harms of current ‘case-finding’ practices.    
As above, the study indicated that an informed 
public may have different priorities than those 
assumed in the clinical guidelines.  
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